Fast-growing Chinese biotech WuXi AppTec debuted on the Hong Kong Stock Exchange on Thursday. The firm’s closing share price was roughly level with its initial public offering (IPO) price of $68 Hong Kong dollars ($9).
WuXi AppTec raised $1 billion in the IPO, a sum which values the firm at just over $10 billion.
The firm is profitable, with revenues of $641 million for the first six months of 2018, an increase of 20% on the same period last year.
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze